Towards Healthcare

RNA Based Therapeutic Companies Strategic Expansion Initiatives, Revenue Diversification, Strategic Joint Ventures, Licensing and Monetization, Peer Comparison Analysis, Leadership and Governance

Date: January 2025

RNA Based Therapeutic Companies, Business & Management Outlook

The global RNA based therapeutic market was evaluated at US$ 6.83 billion in 2023 and is expected to attain around US$ 40.81 billion by 2034, growing at a CAGR of 17.64% from 2024 to 2034.

RNA Based Therapeutic Market Companies

Top Companies in RNA Based Therapeutic Market are:

  • ISIS Pharmaceuticals
  • Quark Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Tekmira Pharmaceuticals Corp.
  • Benitec Biopharma Limited
  • Genzyme Corporation
  • Silence Therapeutics PLC
  • Cenix BioScience GmbH

International Trade Data: Consignee and Shipper Details with HS Code Descriptions

CONSIGNEE_NAME SHIPPER_NAME HS_CODE_DESCRIPTION LOADING_PORT SUMOFQUANTITY SUMOFWEIGHT
SANDOZ INC SANDOZ PRIVATE LIMITED Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms 53313, JAWAHARLAL NEHRU 418236 24340
EUCATEX OF NORTH AMERICA INC EUCATEX INDUSTRIA E COMERCIO LTDA Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents 35177, SAO PAULO 397700 4846000000
RB HEALTH US LLC RECKITT BENCKISER HEALTHCARE UK LIMITED Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms 41251, LIVERPOOL 232401 335893
TIME CAP LABS INC MARKSANS PHARMA LIMITED Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms 53313, JAWAHARLAL NEHRU 201133 845370
ATRIUM MEDICAL CORP HOLOPACK VERPACKUNGSTECHNIK GMBH Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms 42870, BREMERHAVEN 129351 30971
LIFESCAN GLOBAL CORP LIFESCAN SCOTLAND LIMITED Diagnostic or laboratory reagents on a backing, excluding those of heading 3006 41352, CORYTON 114553 111606
AUROLOGISTICS LLC AUROBINDO PHARMA LIMITED Medicaments containing penicillins or derivatives thereof, with a penicillanic acid structure 53313, JAWAHARLAL NEHRU 72927 261709
KUEHNE AND NAGEL S A KUEHNE AND NAGEL N V S A ANTWERPEN Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms 42305, ANVERS 50058 6251
SUMITOMO PHARMA AMERICA INC PIRAMAL PHARMA LIMITED Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms 53313, JAWAHARLAL NEHRU 39833 53745
NEW WORLD IMPORT INC GALENTIC PHARMA INDIA PRIVATE LIMITED Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in dosage forms 53306, MUNDRA 39210 91127

Recent Developments in the RNA Based Therapeutic Market

  • In October 2024, Urban Therapeutics Inc. announced a vision to pioneer the future of RNA interference (RNAi)-based medicine. Urban Therapeutics aims to foster the next generation of small interfering RNA (siRNA) RNAi-based “triggers” to create powerful and sustainable products and expand the broad therapeutic spectrum of RNAi-based medicines.
  • In February 2024, UT Southwestern Medical Center partnered with Pfizer to develop RNA-enhanced delivery technology for gene therapy through Dallas Medical Center’s Genetic Medicine Engineering Program.
  • In November 2024, Maravai LifeSciences, Inc., a global provider of life science reagents and services to scientists and biotechnology innovators, announced its agreement to acquire Officinae Bio's DNA and RNA business. The acquisition will expand Maravai and TriLink BioTechnologies’ ability to help customers develop novel nucleic acid therapies.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com